EMA Executive Director Outlines Priorities

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 12-15-2015 15:16


The European Medicines Agency (EMA) Executive Director Guido Rasi outlined his vision for his five-year mandate at the helm of the EMA at a press briefing. Rasi took office as executive director of the EMA on November 16, 2015 for a five-year term.

Among the current shifts in medicines development, Professor Rasi mentioned the vast progress made in the understanding of the human body and the underlying science, the increased globalization of medicines development and manufacturing, as well as the current pressure on healthcare systems. "I am confident that EMA, working closely with the national competent authorities in Member States, is ready to successfully address these new challenges," he said.

To that end, he outlined the EMA's key priorities: (1) focusing on research and development for medicines that address public health needs; (2) commitment to transparency; (3) patient involvement; (4) best use of all available evidence: and (5) making the EMA a global reference authority for the regulation of medicines. To address these challenges, Professor Rasi noted the importance to strengthen the cooperation with the European Union member states, the European Commission, and other European and international partners, and to bring communities and stakeholders involved closer together for a more holistic approach to medicines evaluation and surveillance across the whole lifespan of a medicine.

Source: European Medicines Agency


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription